Wang J, Guo Z-Z, Wang Y-J, Zhang S-G, Xing D-G
Department of Neurosurgery, The First Hospital of China Medical University, No 155 Nanjing North Street, Heping Ward, Shenyang 110001, China.
Department of Neurosurgery, The First Hospital of China Medical University, No 155 Nanjing North Street, Heping Ward, Shenyang 110001, China.
Eur J Surg Oncol. 2014 Sep;40(9):1062-71. doi: 10.1016/j.ejso.2013.11.024. Epub 2013 Dec 14.
Primary malignant intracranial melanomas are rare tumors of the central nervous system. These tumors are highly malignant and are associated with poor prognosis. The field of neurosurgery has struggled with the diagnosis and treatment of these tumors.
In this study, we present a surgical series of eight patients with primary malignant intracranial melanomas and retrospectively analyze the clinical features, imaging findings, pathological features and prognoses of these patients.
All patients underwent microsurgery. Total and subtotal resection of the tumor was achieved in six and two patients, respectively. Of the eight patients, seven showed improvement while one remained the same at time of discharge. There was no neurosurgical deterioration. Radiotherapy was conducted in six patients after operation. The average follow-up duration was 13.8 months (range = 9-26 months). During the follow-up period, three patients died from this disease. One patient suffered from recurrence at the 16th month and underwent second surgery. The other patients were still alive with no evidence of tumor recurrence.
Microsurgery and radiotherapy should be the first line managements for patients with primary malignant intracranial melanomas. Improvements in chemotherapy, immunotherapy and targeted therapies may provide more effective treatments for malignant intracranial melanomas.
原发性恶性颅内黑色素瘤是中枢神经系统的罕见肿瘤。这些肿瘤具有高度恶性,且预后较差。神经外科领域在这些肿瘤的诊断和治疗方面面临困难。
在本研究中,我们展示了一组8例原发性恶性颅内黑色素瘤患者的手术病例,并回顾性分析了这些患者的临床特征、影像学表现、病理特征及预后。
所有患者均接受了显微手术。分别有6例和2例患者实现了肿瘤全切和次全切。8例患者中,7例在出院时病情改善,1例无变化。未出现神经外科相关的病情恶化。6例患者术后接受了放疗。平均随访时间为13.8个月(范围=9 - 26个月)。随访期间,3例患者死于该疾病。1例患者在第16个月复发并接受了二次手术。其他患者仍存活,无肿瘤复发迹象。
显微手术和放疗应作为原发性恶性颅内黑色素瘤患者的一线治疗手段。化疗、免疫治疗和靶向治疗的进展可能为恶性颅内黑色素瘤提供更有效的治疗方法。